Hamann Lutz, Gomma Abuzeid, Schröder Nicolas W J, Stamme Cordula, Glaeser Christiane, Schulz Susanne, Gross Michael, Anker Stefan D, Fox Kim, Schumann Ralf R
Institute for Microbiology and Hygiene, Charité University Medical Center, Humboldt University, Dorotheenstrasse 96, 10117 Berlin, Germany.
J Mol Med (Berl). 2005 Jun;83(6):478-85. doi: 10.1007/s00109-005-0643-7. Epub 2005 May 4.
Restenosis is a major problem for patients undergoing percutaneous transluminal coronary angioplasty (PTCA). Inflammatory processes and genetic factors have been suggested to be involved in the pathogenesis of both atherosclerosis and restenosis. The recently discovered family of Toll-like receptors (TLRs) consists of molecules that initiate signaling after host-pathogen interactions. Recently it has been shown that the TLRs are involved in the development and progression of atherosclerosis by interfering with lipid metabolisms and by mediating inflammation. TLR-2 is a key innate immunity receptor for sensing both endogenous inflammatory mediators and ligands of several microbial pathogens postulated to be involved in atherosclerosis. A frequent single nucleotide polymorphism (SNP) for the TLR-2 gene, resulting in a non-functional receptor, has been described. By genotyping two independent groups of patients receiving PTCA, followed by stent implantation in one group, we found a significantly enhanced frequency of the TLR-2 Arg753Gln SNP in patients with restenosis as compared to those without restenosis (PTCA: 7.21 versus 2.45%, P = 0.014; PTCA/stent: 6.86 versus 1.53%, P = 0.013). In contrast, a common TLR-4 SNP was similarly distributed among the patient groups investigated. We furthermore compared the frequency of both SNPs in the patients with an age-matched group of individuals without atherosclerosis and found a trend towards a lower frequency of the TLR-4 SNP in the atherosclerotic group (PTCA: 5.58; PTCA/stent: 3.85 versus 7.14%). We conclude that in restenosis a functional TLR-2 is protective and potentially involved in a reaction pattern preventing restenosis. Screening for the TLR-2 Arg753Gln SNP may be of importance for stratifying a patient's risk and for preventive and therapeutic measures.
再狭窄是接受经皮腔内冠状动脉成形术(PTCA)患者面临的一个主要问题。炎症过程和遗传因素被认为与动脉粥样硬化和再狭窄的发病机制有关。最近发现的Toll样受体(TLR)家族由宿主与病原体相互作用后启动信号传导的分子组成。最近有研究表明,TLR通过干扰脂质代谢和介导炎症反应参与动脉粥样硬化的发生和发展。TLR-2是一种关键的天然免疫受体,可感知内源性炎症介质以及几种推测与动脉粥样硬化有关的微生物病原体的配体。已经描述了TLR-2基因常见的单核苷酸多态性(SNP),该多态性会导致受体无功能。通过对两组接受PTCA的独立患者进行基因分型,其中一组随后植入支架,我们发现与无再狭窄的患者相比,再狭窄患者中TLR-2 Arg753Gln SNP的频率显著增加(PTCA组:7.21% 对2.45%,P = 0.014;PTCA/支架组:6.86% 对1.53%,P = 0.013)。相比之下,常见的TLR-4 SNP在研究的患者组中分布相似。我们还比较了这些SNP在患者与年龄匹配的无动脉粥样硬化个体组中的频率,发现动脉粥样硬化组中TLR-4 SNP的频率有降低趋势(PTCA组:5.58;PTCA/支架组:3.85% 对7.14%)。我们得出结论,在再狭窄中,功能性TLR-2具有保护作用,并可能参与预防再狭窄的反应模式。筛查TLR-2 Arg753Gln SNP对于评估患者风险以及采取预防和治疗措施可能具有重要意义。